May 17, 2019 / 10:00 PM / 9 days ago

Allergan wins less than $50,000 in case against compounder Imprimis

A federal jury on Thursday awarded Allergan PLC less than $50,000 of the millions of dollars it sought in a false advertising lawsuit seeking to stop Imprimis Pharmaceuticals Inc from selling certain compounded drugs that bypass regulatory approval, including a cheaper alternative to Allergan’s dry eye drug Restasis, according to a lawyer for Imprimis.

Daniel Rasmussen of Payne & Fears, a lawyer for Imprimis, said the jury did not explain how it arrived at the $48,500 verdict, which was handed down in Santa Ana, California, federal court. Allergan had sought more than $7 million, according to Rasmussen.

To read the full story on WestlawNext Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below